Baxter International (NYSE:BAX – Get Free Report) will be releasing its earnings data before the market opens on Tuesday, August 6th. Analysts expect Baxter International to post earnings of $0.66 per share for the quarter. Baxter International has set its Q2 guidance at $0.65-$0.67 EPS and its FY24 guidance at $2.88-$2.98 EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.
Baxter International (NYSE:BAX – Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.04. Baxter International had a return on equity of 18.47% and a net margin of 17.79%. The company had revenue of $3.59 billion for the quarter, compared to the consensus estimate of $3.55 billion. During the same quarter last year, the company earned $0.59 EPS. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. On average, analysts expect Baxter International to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Baxter International Stock Up 1.4 %
NYSE BAX opened at $36.01 on Tuesday. Baxter International has a 12 month low of $31.01 and a 12 month high of $47.19. The company has a current ratio of 1.48, a quick ratio of 1.01 and a debt-to-equity ratio of 1.35. The stock has a market cap of $18.35 billion, a PE ratio of 6.93, a P/E/G ratio of 1.85 and a beta of 0.57. The stock’s 50 day moving average is $34.12 and its 200 day moving average is $38.07.
Baxter International Announces Dividend
Analyst Upgrades and Downgrades
A number of analysts have issued reports on the stock. TD Cowen downgraded shares of Baxter International from a “buy” rating to a “hold” rating and set a $40.00 price target on the stock. in a report on Friday, May 10th. Evercore ISI cut their price target on shares of Baxter International from $46.00 to $45.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Citigroup decreased their price objective on shares of Baxter International from $38.00 to $37.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. StockNews.com downgraded Baxter International from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. Finally, Morgan Stanley downgraded Baxter International from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $39.00 to $30.00 in a research report on Monday, July 15th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Baxter International currently has a consensus rating of “Hold” and a consensus target price of $42.55.
View Our Latest Stock Analysis on BAX
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
See Also
- Five stocks we like better than Baxter International
- Canadian Penny Stocks: Can They Make You Rich?
- Should You Invest in Bonds? Here’s What to Know
- Golden Cross Stocks: Pattern, Examples and Charts
- Why This Manufacturer is Committing to a Massive Buyback Program
- Best Stocks Under $10.00
- Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.